Suppr超能文献

在强心苷的12β-羟基与洋地黄受体的相互作用中受到影响的人类细胞突变体。

Human cell mutants affected in the interaction of the 12 beta-OH group of cardiac glycosides with the digitalis receptor.

作者信息

Gupta R S, Chopra A

机构信息

Department of Biochemistry, McMaster University, Hamilton, Ontario, Canada.

出版信息

Biochem Pharmacol. 1987 Nov 15;36(22):3829-33. doi: 10.1016/0006-2952(87)90445-x.

Abstract

The cross-resistance patterns of two different types of mutants of HeLa cells selected for resistance to the digoxin analog SC4453 (SCR mutants) in which the Na+/K+-ATPase is affected [A. Chopra and R. S. Gupta, J. biol. Chem. 261, 2034 (1986)], and towards numerous cardiac glycosides (CGs) and genins, were examined. One type of SCR mutant (designated as group C) was highly resistant to all CGs and genins investigated. In contrast, the other type of SCR mutant (group D) showed a high degree of cross-resistance towards selected CG derivatives (viz. digoxin, SC4453, digoxigenin, lanatoside C, alpha- and beta-methyldigoxin, dihydrodigoxin, alpha- and beta-acetyldigoxin, alpha,beta-diacetyldigoxin), all of which contained a free 12 beta-OH group in the steroid structure. Slight cross-resistance of the group D mutants was also observed for other compounds (viz. ouabain, ouabagenin, dihydroouabain) that contain a free 11 alpha-OH group in the molecule. However, these mutants exhibited no cross-resistance to other CG derivatives, which either lacked the above groups (viz. digitoxin, digitoxigenin, dihydrodigitoxin, digitoxigenin mono- and bisdigitoside, nerifolin, gitoxigenin, gitoxin, 16-acetylgitoxin, lanatosides A and B, cymarin, convallatoxin, oleandrin, strophanthidin, actodigin and bufalin) or in which the 12 beta-OH group was acetylated (viz. as in the case of 12-acetyldigoxin). Since the 12 beta-OH group is not required for CG-like activity, to account for these observations it is suggested that the genetic lesion in the group D mutant leads to the creation of a new binding site in the digitalis receptor, which specifically interacts with the 12 beta-OH group (the site presumably also interacts weakly with the 11 alpha-OH group) and either prevents or distorts the binding of the compounds to the drug binding site on the receptor. Further investigations with the different classes of CG-resistant mutants at the molecular level should prove very useful in identifying the drug receptor site and in understanding how these drugs interact with it.

摘要

研究了两种不同类型的对洋地黄毒苷类似物SC4453(SCR突变体)产生抗性的HeLa细胞突变体的交叉抗性模式,其中Na+/K+-ATP酶受到影响[A. Chopra和R. S. Gupta,《生物化学杂志》261, 2034 (1986)],并检测了它们对多种强心苷(CGs)和苷元的抗性。一种类型的SCR突变体(指定为C组)对所有研究的CGs和苷元具有高度抗性。相比之下,另一种类型的SCR突变体(D组)对选定的CG衍生物(即洋地黄毒苷、SC4453、洋地黄毒苷元、毛花苷C、α-和β-甲基洋地黄毒苷、二氢洋地黄毒苷、α-和β-乙酰洋地黄毒苷、α,β-二乙酰洋地黄毒苷)表现出高度交叉抗性,所有这些衍生物在甾体结构中都含有一个游离的12β-OH基团。D组突变体对分子中含有游离11α-OH基团的其他化合物(即哇巴因、哇巴因苷元、二氢哇巴因)也表现出轻微交叉抗性。然而,这些突变体对其他CG衍生物没有交叉抗性,这些衍生物要么缺乏上述基团(即地高辛、地高辛苷元、二氢地高辛、地高辛苷元单糖苷和双糖苷、夹竹桃苷、羟基洋地黄毒苷元、吉托辛、16-乙酰吉托辛、毛花苷A和B、 cymarin、铃兰毒苷、夹竹桃苷、毒毛旋花子苷元、阿克托地辛和蟾毒灵),要么12β-OH基团被乙酰化(即如12-乙酰洋地黄毒苷的情况)。由于CG样活性不需要12β-OH基团,为了解释这些观察结果,有人提出D组突变体中的基因损伤导致在洋地黄受体中产生一个新的结合位点,该位点与12β-OH基团特异性相互作用(该位点可能也与11α-OH基团弱相互作用),并阻止或扭曲化合物与受体上药物结合位点的结合。在分子水平上对不同类型的CG抗性突变体进行进一步研究,对于确定药物受体位点以及理解这些药物如何与其相互作用应该非常有用。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验